Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €60.10 EUR
Change Today +0.221 / 0.37%
Volume 0.0
JUD On Other Exchanges
New York
As of 1:40 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

One St. Jude Medical Drive

St. Paul, MN 55117

United States

Phone: 651-756-2000

Fax: 651-756-3301

St. Jude Medical, Inc. is engaged in the development, manufacture, and distribution of cardiovascular medical devices for the global cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The company’s principal products in each business unit are as follows: Implantable Electronic Systems Division (IESD) – tachycardia implantable cardioverter defibrillator systems (ICDs), bradycardia pacemaker systems (pacemakers) and neurostimulation products (spinal cord and deep brain stimulation devices); and Cardiovascular and Ablation Technologies Division (CATD) – vascular products (vascular closure products, pressure measurement guidewires, optical coherence tomography (OCT) imaging products, vascular plugs and other vascular accessories), structural heart products (heart valve replacement and repair products and structural heart defect devices) and atrial fibrillation (AF) products (electrophysiology (EP) introducers and catheters, advanced cardiac mapping, navigation and recording systems and ablation systems). Principal Products Implantable Electronic Systems Division IESD is focused on the cardiac rhythm management and neuromodulation therapy areas. The company’s cardiac rhythm management devices include ICDs that provide life-saving therapy to patients suffering from lethal heart conditions, such as sudden cardiac arrest; cardiac resynchronization therapy (CRT) devices to save and improve the lives of patients suffering from heart failure (HF); pacemakers to help patients whose hearts beat too slowly or who suffer from other debilitating cardiac arrhythmias; leads (wires that connect its devices to the heart) to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment which are used by physicians and healthcare professionals to program its cardiac rhythm management devices and analyze device data to improve patient management. The company’s neuromodulation product offerings provide neurostimulation treatment in which an implantable device delivers electrical directly to targeted nerve sites. The company’s commercialized neurostimulation therapies include spinal cord stimulation (SCS) for the treatment of chronic pain, deep brain stimulation (DBS) for treating the symptoms of Parkinson's disease and peripheral nerve stimulation (PNS) for the treatment of chronic migraine headache. ICD Systems: The company’s ICDs and cardiac resynchronization therapy defibrillator (CRT-D) devices treat patients with hearts that beat inappropriately fast, a condition known as tachycardia. ICDs monitor the heartbeat and deliver high energy electrical impulses, or ‘shocks,’ to treat potentially lethal, abnormally fast heart rhythms (ventricular tachycardia (VT) and ventricular fibrillation (VF)), which often lead to sudden cardiac death (SCD). The company received U.S. Food and Drug Administration (FDA) approval in June 2013 and European CE Mark approval in May 2013 for its next generation Ellipse ICD and Assura family of ICD and CRT-D devices. The Assura family of high-voltage devices features both ICD models (Fortify Assura) and CRT-D models (Unify Assura for bi-polar CRT-D and Quadra Assura for quadripolar CRT-D). The Ellipse ICD is a high energy ICD denoted for its small size while the Assura family has a high energy output, with a maximum output of 40 Joules. The Assura families also include its Unify Quadra CRT-D device and its Quartet LV. The company’s Unify Quadra, Quadra Assura and Promote Quadra systems allow physicians more options to address pacing complications without the need to reposition a lead surgically. In 2013, the company announced European CE Mark approval of its next-generation quadripolar device, the Quadra Assura MP CRT-D device. The company’s quadripolar devices feature MultiPoint Pacing (MPP) technology that enables physicians to pace multiple locations on the left side of the heart with a single lead, thereby providing more options to optimize CRT pacing to meet individual patient needs. The Assura family repla


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €60.10 EUR +0.221

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.83 USD +0.39
Olympus Corp ¥4,450 JPY -10.00
Smith & Nephew PLC 1,142 GBp -6.00
Terumo Corp ¥3,225 JPY -45.00
Zimmer Holdings Inc $117.50 USD +1.85
View Industry Companies

Industry Analysis


Industry Average

Valuation JUD Industry Range
Price/Earnings 19.0x
Price/Sales 3.4x
Price/Book 4.5x
Price/Cash Flow 16.9x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at